Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9844510 | LAB HRA PHARMA | Ulipristal acetate tablets |
Dec, 2028
(5 years from now) | |
US8735380 | LAB HRA PHARMA | Ulipristal acetate tablets |
Feb, 2029
(6 years from now) | |
US10159681 | LAB HRA PHARMA | Method for on-demand contraception |
Apr, 2030
(7 years from now) | |
US10772897 | LAB HRA PHARMA | Method for on-demand contraception |
Apr, 2030
(7 years from now) | |
US9283233 | LAB HRA PHARMA | Method for on-demand contraception |
Apr, 2030
(7 years from now) | |
US8512745 | LAB HRA PHARMA | Ulipristal acetate tablets |
Jun, 2030
(7 years from now) | |
US8426392 | LAB HRA PHARMA | Method for providing emergency contraception |
Jun, 2030
(7 years from now) | |
US8962603 | LAB HRA PHARMA | Method for post coital contraception in overweight or obese female subjects using ulipristal acetate |
Jun, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Jun 24, 2024 |
Drugs and Companies using ULIPRISTAL ACETATE ingredient
Market Authorisation Date: 13 August, 2010
Treatment: A method for contraception comprising the step of oral administration a dosage of 20 mg to 30 mg of ulipristal acetate to a woman within 72 hours and up to 120 hours after an unprotected intercourse; A method for contraception, the method comprising administering a tablet comprising 20 mg to 30 mg of ulipristal acetate to a woman within 120 hours after an unprotected intercourse; Method for contraception to a woman comprising administering to the woman 30mg of ulipristal acetate more than 72 hours and up to 120 hours after an unprotected intercourse; Ella is a progesterone agonist/antagonist emergency contraception indicated for the prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. ella can be taken with or without food; Method for providing post coital contraception to a woman by administering about 30 mg of ulipristal acetate within about 120 hours after intercourse, wherein the woman is overweight having a bmi of 25 to 29.99
Dosage: TABLET;ORAL
18
United States
8
European Union
4
Japan
3
China
3
New Zealand
2
Hong Kong
2
RS
2
Australia
2
Poland
2
Lithuania
2
Spain
2
Cyprus
2
Slovenia
2
Hungary
2
South Africa
2
Portugal
2
Russia
2
Croatia
2
San Marino
2
Canada
2
Denmark
1
Korea, Republic of
1
Brazil
1
Ukraine
1
Israel
1
Mexico
1
Colombia
1
ME
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic